MedTrace Logo

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

NCT03511365 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-01-07

No results posted yet for this study

Summary

Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination. The probiotic formulation VSL#3 450 Billion CFU twice daily will be administered for 8 weeks and the determination of Il-17 and microbiome will be repeated. Each subject will serve as his or her own control.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Probiotics MeSH Descriptor Data 2018
  • Interleukin-17 MeSH Descriptor Data 2018

Interventions

BIOLOGICAL

Probiotic Formulation VSL#3

Probiotic VSL#3 administration.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2018-12-14
Completion
2019-10-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03511365 on ClinicalTrials.gov